Skip to main content
. 2020 Jan 9;11:147. doi: 10.1038/s41467-019-13837-4

Fig. 3. TLR8 enhances cytokine secretion and surface activation markers in CD4+ T cells.

Fig. 3

a CD4+ T cells were pre-treated with 5 µM TLR8-specific inhibitors CU-CPT9a, CU-CPT9b, or the negative control compound CU-CPT6, prior to TCR activation and stimulation with synthetic TLR ligands (5 µg/ml). Cell supernatants were harvested at 24 h and IFN-γ, IL-17, and IL-1β analyzed using multiplex ELISA. Bars represent mean values + SEM from five independent experiments. b TCR-activated CD4+ T cells were stimulated with 5 μg/ml CL264, R848 (TLR7/8), CL75, pU/pLA, or CpG (TLR9, 5 μM). T cell activation markers were analyzed by flow cytometry at the indicated time points after surface staining for CD25, CD40L, CD69, CD80, HLA-DR, and PD-1. Graphs represent mean values ± SEM from three independent experiments. Statistical significance was determined in a by ANOVA with Dunnettʼs post-test, in b by area under the curve (AUC) calculation followed by one-way ANOVA with Dunnettʼs post-test on log-transformed data; significance levels: *p < 0.05; **p < 0.01; ***p < 0.001. Source data are provided as a Source Data File.